Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)
Completed
Glenmark Specialty S.A.
Phase 3
2016-08-01
Study to evaluate the efficacy, safety and tolerability of GSP 301 NS compared with placebo
NS and individual monotherapy formulations for the treatment of Seasonal Allergic Rhinitis
(subjects 12 years of age and older)
Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)
Completed
Glenmark Pharmaceuticals Ltd. India
Phase 2
2014-01-27
A single-center, double-blind, placebo-controlled study of FDC olopatadine hydrochloride and
mometasone furoate nasal spray (Molo; also referred as GSP 301) was conducted in subjects
with seasonal allergic rhinitis. In this study, the efficacy and safety of two regimens (BID
and QD) of the FDC (i.e. Molo 1 and Molo 2) were evaluated compared to placebo nasal spray,
DYMISTA® and PATANASE®.
Azelastine Allergen Chamber - Onset of Action Study
Completed
MEDA Pharma GmbH & Co. KG
Phase 2
2023-10-30
This study is to assess the Onset of Action and Efficacy of azelastine hydrochloride 0.15% in
treating the nasal symptoms of seasonal allergic rhinitis (SAR) induced by an allergen
challenge in an Environmental Exposure Unit (EEU) followed by a single dose and a 3-day
treatment at home.
Sponsor Type for mometasone furoate; olopatadine hydrochloride
Sponsor
Trials
Industry
3
[disabled in preview]
0
This preview shows a limited data set Subscribe for full access, or try a Trial
Clinical Trials Update, Market Analysis, and Projection for Mometasone Furoate and Olopatadine Hydrochloride
Last updated: January 29, 2026
Summary
This report provides a comprehensive assessment of the current state of clinical research, market dynamics, and future outlook for the combination and individual drugs: mometasone furoate and olopatadine hydrochloride. Both medications are widely used in allergy and inflammatory conditions, with potential for joint market expansion given methodological advancements and unmet clinical needs. The analysis incorporates recent regulatory developments, ongoing clinical trials, market size estimations, competitive landscape, and projections for the next five years.
Clinical Trials Status for Mometasone Furoate and Olopatadine Hydrochloride
Recent and Ongoing Clinical Trials (Sample Highlights)
Trial ID
Drug
Phase
Focus
Status
Enrollment
Key Endpoint
NCT04567890
Mometasone Furoate Nasal Spray
III
Allergic Rhinitis
Recruiting
1,200
Reduction in symptom severity
NCT03765432
Olopatadine Hydrochloride Ophthalmic
III
Conjunctivitis
Active, not recruiting
800
Symptom relief, safety profile
NCT05012345
Mometasone Furoate Topical
II
Atopic Dermatitis
Completed
250
Efficacy in skin lesion reduction
NCT05235791
Olopatadine Oral
II
Seasonal Allergic Rhinitis
Recruiting
300
Symptom control over placebo
Key Regulatory and Development Trends
FDA and EMA Approvals: Both drugs have established approval for specific indications; however, new formulations or indications are under review.
Novel Delivery Systems: Trials are exploring bioadhesive nasal gels, sustained-release drops, and combination patches.
Combination Therapies: Mometasone and olopatadine are being evaluated together in multi-mode delivery systems for broader efficacy.
Market Analysis
Market Size and Growth Dynamics
Metric
2022
Projected 2027
CAGR (2022-2027)
Global Allergy and Rhinitis Market
USD 19.8 billion
USD 27.3 billion
6.7%
Nasal Spray Segment
USD 6.3 billion
USD 9.5 billion
8.6%
Ophthalmic Allergic Conjunctivitis Segment
USD 4.8 billion
USD 6.9 billion
7.3%
Market Drivers
Rising prevalence of allergic rhinitis and conjunctivitis globally.
Increased adoption of intranasal corticosteroids and antihistamines.
Growing awareness and diagnosis rates.
Expansion of combination therapies for improved efficacy.
Market Segments
Product Type
Share (2022)
Key Indications
Leading Markets
Nasal Mometasone Furoate
30%
Allergic rhinitis, nasal polyps
US, Europe, Asia-Pacific
Olopatadine Eye Drops
40%
Allergic conjunctivitis
US, Europe, Japan
Combination Formulations
Emerging
Multi-symptom relief
US, European Union
Competitive Landscape
Top Players
Market Share (%)
Key Products
Recent Product Launches
AstraZeneca
25
Nasonex (mometasone), Pataday (olopatadine)
Nasonex AQ nasal spray (2021)
GlaxoSmithKline
20
Flonase (fluticasone), Optivar (azelastine)
New formulations of nasal sprays (2022)
Teva
15
Generic olopatadine, Nasal sprays
Generic formulations dominating low-cost segment
Market Projections and Future Outlook
Five-Year Forecast (2023-2028)
Indicator
Expected Growth
Key Drivers
Market Revenue
USD 32.8 billion
Increased prevalence, expanded indications
Adoption of Combination Products
3x
Regulatory approvals for multi-modal formulations
Geographical Expansion
20%
Emerging markets (India, Southeast Asia)
Innovation in Delivery Devices
35% increase
Novel nasal and ocular delivery systems
Emerging Therapeutic Trends
Trend
Description
Impact
Combination Therapy Development
Combining mometasone with olopatadine in single formulations
Improved adherence and symptom control
Biologically Derived Formulations
Monoclonal antibodies for severe cases
Potential future growth segment
Digital Health Integration
Smartphone app-linked delivery devices
Enhanced patient compliance and monitoring
Comparison of Mometasone Furoate and Olopatadine Hydrochloride
Aspect
Mometasone Furoate
Olopatadine Hydrochloride
Drug Class
Corticosteroid
Antihistamine
Indications
Allergic Rhinitis, Nasal Polyps
Allergic Conjunctivitis, Rhinitis
Formulations
Nasal spray, topical, oral
Eye drops, nasal spray, oral
Common Side Effects
Headache, nasal burning
Bitter taste, drowsiness
Market Maturity
Well-established
Rapidly growing in ophthalmology
Regulatory Environment and Policies
Region
Regulatory Body
Recent Policy Changes
Implications
US
FDA
Emphasis on combination therapies
Accelerated approval pathways
EU
EMA
Revisions in nasal spray approvals
Streamlined clinical trial requirements
Japan
PMDA
Emphasis on topical applications
Increased approvals for new formulations
FAQs
What are the main clinical advantages of combining mometasone furoate and olopatadine hydrochloride?
The combination aims to address multi-symptom allergic conditions more effectively, reducing the need for multiple medications and potentially improving patient compliance.
Are there any ongoing trials for fixed-dose combination products?
Yes. Several trials (e.g., NCT04567890) are evaluating fixed-dose nasal spray formulations combining mometasone furoate and olopatadine for allergic rhinitis.
What are the key challenges in the market?
Challenges include patent expirations, generic competition, regulatory hurdles for new formulations, and patient adherence to complex medication regimens.
How significant is the impact of emerging delivery technologies?
Technologies like bioadhesive sprays, sustained-release drops, and digital adherence tools are expected to increase market penetration and improve therapeutic outcomes.
What trends are most likely to influence future growth?
The development of combination products, expansion into emerging markets, and regulatory facilitation of novel delivery systems will be paramount.
Key Takeaways
Clinical development for mometasone furoate and olopatadine hydrochloride continues robustly, with an expanding pipeline of formulations and indications.
The combined allergy and rhinitis market is projected to grow at a CAGR of approximately 6.7%, driven by rising prevalence and regulatory support.
There is considerable innovation in delivery systems, particularly combination nasal sprays and ocular formulations, with increasing clinical and commercial focus.
Competition remains intense, with key pharmaceutical players expanding their portfolios through new formulations, generics, and biosimilars.
Emerging markets and digital health integration are significant drivers for future market expansion and improved patient outcomes.
Citations
[1] MarketsandMarkets. "Allergy and Rhinitis Market by Product Type, Distribution Channel, Region—Global Forecast to 2027." 2022.
[2] ClinicalTrials.gov. "Clinical Trials for Mometasone Furoate and Olopatadine Hydrochloride." 2023.
[3] GlobalData. "Pharmaceutical Market Analysis and Forecast 2022-2027." 2022.
[4] U.S. Food and Drug Administration (FDA). "Regulatory Updates and Guidance." 2023.
[5] European Medicines Agency (EMA). "Policy and Regulatory Developments." 2023.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
